尼可地尔对慢性缺血性心肌病合并心力衰竭患者的临床疗效及安全性研究  

Clinical efficacy and safety of nicorandil for chronic ischemic cardiomyopathy patients with heart failure

作　　者：黄伟胜[1] 罗森华 罗伟祥[1] 

机构地区：[1]广东省梅州市大埔县人民医院心内科,514299

出　　处：《实用医学杂志》2016年第15期2544-2547,共4页The Journal of Practical Medicine

摘　　要：目的:探讨尼可地尔对慢性缺血性心肌病合并心力衰竭患者的临床疗效及安全性。方法:按照随机数字表法将我院收治的慢性缺血性心肌病合并心力衰竭患者分为两组,对照组常规抗心衰治疗及对症支持治疗,观察组在对照组治疗方案上口服尼可地尔。治疗6个月,比较两组的临床疗效及安全性。结果:观察组心功能改善情况明显优于对照组,差异有统计学意义(Z=-2.302,P=0.021)。两组治疗后的左心室射血分数(LVEF)、6 min步行距离大于治疗前,左心室收缩末内径(LVESD)、左心室舒张末内径(LVEDD)小于治疗前,且观察组治疗后LVEF、6 min步行距离大于对照组,LVESD、LVEDD小于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率9.59%,对照组6.94%,两组差异无统计学意义(χ2=0.334,P=0.563)。结论 :在常规抗心衰治疗基础上口服尼可地尔可显著提高慢性缺血性心肌病合并心力衰竭患者的临床疗效,改善患者心功能,且无明显不良反应,患者耐受性好。Objective To explore the clinical efficacy and safety of nicorandil in the treatment of chronic ischemic cardiomyopathy patients with heart failure. Methods The chronic ischemic cardiomyopathy patients with heart failure in our hospital were divided into two groups according to the random number table method.Control group underwent conventional anti heart failure treatment and symptomatic supportive treatment, and treatment group was treated by the nicorandil in addition to above treatments. After treatment for 6 months,comparisons of clinical efficacy and safety between two groups were conducted. Results The improvement of heart function in observation group was better than that in control group（Z =-2.302, P = 0.021）. After treatment, the LVEF, 6 min walking distance were greater than those before treatment, and the LVESD, LVEDD were less than those before treatment（P〈0.05）. The LVEF, 6 min walking distance in observation group after treatment were greater than those in control group and the LVESD, LVEDD were less than those in control group（P〈0.05）. The incidence rate of adverse reaction in observation group was 9.59%, and 6.94% in control group, without statistical difference between two groups（χ^2= 0.334,P = 0.563）. Conclusion In addition to conventional anti heart failure treatment, nicorandil can significantly improve the curative effect and the heart function in the treatment of chronic ischemic cardiomyopathy patients with heart failure and there are no significant adverse reactions. In addition, patients are tolerant.

关 键 词：尼可地尔 慢性缺血性心肌病 心力衰竭 

分 类 号：R542.2[医药卫生—心血管疾病] R541.6[医药卫生—内科学]